The Antibody Society has partnered with numerous conference organizers, including Informa Connect, Cambridge Healthtech Institute, Hanson Wade, and Terrapinn, to ensure our members receive substantial discounts on meeting registration fees. As a courtesy, we also list meetings held by non-profit organizations, such as Gordon Research Conferences and KeyStone Symposia.
We have also partnered with Schrödinger, and are pleased to offer 10% discounts to our members for their online course, Introduction to Computational Antibody Engineering.
To access the discount codes, please log into website and navigate to the Member discount codes page in the Members Only area.
Schrödinger’s online course, Introduction to Computational Antibody Engineering, will show how industry-leading computational molecular modeling solutions are used to aid in antibody discovery and design and how to incorporate these computational approaches into your research project. This course will also provide a chance to work hands-on with Schrödinger’s BioLuminate software.
Upcoming 2024 session dates:
- January 9, 2024 – February 14, 2024
- January 23, 2024 – February 28, 2024
- February 6, 2024 – March 13, 2024
- February 20, 2024 – March 27, 2024
- March 5, 2024 – April 3, 2024
- March 19, 2024 – April 17, 2024
The Antibody Society members save 10% off your booking – log into the Members Only area or contact membership@antibodysociety.org for the discount code.
March 2024
10th Alpbach Workshop on Affinity Proteomics
11th to 13th March 2024, Alpbach, Austria
Engage in scientific discussion and networking in awe-inspiring scenery!
The Alpbach workshop is regarded as one of the best meetings on antibodies and other protein-binding molecules and their role in defining the proteome. The combination of excellent science with mountain scenery and winter sports creates an atmosphere that makes this series of workshops exceptional.
Please email info@affinityproteomicsalpbach.com if you are interested the upcoming workshop in March 2024. Space is limited!
We find ourselves at the cutting edge of oncology innovation, with the ADC field booming with excitement due to the constant eflux of clinical progress and a plethora of high-value collaborations.
As such the 14th World ADC London 2024 returns this March as a crucial touchpoint for all antibody drug conjugate developers across Europe.
This meeting is the place where innovation meets collaboration to drive antibody-drug conjugates forward and transform cancer therapy as we know it. Uniting 600+ industry experts and ADC newcomers, this is a conversation you can’t afford to miss.
View the full agenda here.
Embark on a knowledge-rich adventure as we explore the intricate nuances of ADC development. From the initial stages of target identification and antibody engineering to the complexities of clinical trials and CMC strategies to navigating commercialisation, expect to leave this event with a comprehensive understanding of the entire ADC lifecycle.
Whether you are pioneering ADC discoveries, accelerating your conjugate through preclinical and clinical development, or optimising your CMC efforts, this is your chance to ahead of the curve with the high-quality and invaluable guidance of the supportive ADC community.
Book your ticket here with Antibody Society’s exclusive code TABS10 and get 10% off your ticket.
As large pharma companies turn to prioritize their R&D investments into neuroscience and capitalize on CNS momentum for 2024, plus existing pharma and biotech continue to expand their dedicated neuroimmunology labs, neuroimmunological targets, including TREM2, RIPK1, and ferroptosis are hotter than ever.
However, there are still translational hurdles to see the breakthrough clinical success of neuroinflammatory modulators to treat Alzheimer’s, Parkinson’s, MS, and beyond.
Showcasing biopharma’s latest data and research spanning discovery to early clinical development, the 6th Neuroimmunology Drug Development Summit is the industry-choice, comprehensive forum harnessing state-of-the-art microglial iPSCs, in vivo models, and neuroinflammatory biomarkers to accelerate neuroinflammatory-targeted drugs into the clinic.
Uniting 100+ CNS experts from Sanofi, Vigil Neuroscience, Roche, Alector, Biogen, BMS, and Muna Therapeutics, this is biopharma’s must-attend meeting for anyone working within neuroimmunology biology, discovery, preclinical, translational, biomarker, and early clinical research looking to translate their neuroimmunological targets into the clinic to develop transformative therapeutics for neurological disorders.
Antibody Society members save 10% off the conference registration– contact membership@antibodysociety.org or visit the Members Only section of the website to find the discount code.
April 2024
Adaptive immune receptors are not only key mediators of the immune response but are also the basis for hundreds of approved therapeutics and diagnostics. Throughout this one-day meeting, we will hear from world-leading computational researchers who develop and apply in silico methods such as structure-aware machine learning to predict the characteristics of antibodies, nanobodies, and T-cell receptors. This includes the evolving fields of structure and conformational ensemble prediction, repertoire immunoinformatics, and biopharmaceutical informatics: from developability prediction to binder design based on grafting, mutational, or de novo approaches.
Confirmed speakers: Professor Peter Tessier (University of Michigan; Keynote), Professor Charlotte Deane (University of Oxford; Keynote), Dr. Paula Dobrinic (Immunocore), Dr. Joseph Watson (University of Washington), Dr. Monica Fernández-Quintero (Scripps Institute, California), Dr. Pietro Sormanni (University of Cambridge)
A poster session will take place over lunch; three talk slots (15 min talk + 5 minute questions) will be allocated on merit from consenting poster abstracts submitted by 23:59 GMT on Friday 9th February, 2024.
Registration is open – please register early as spaces are limited.
Early Bird Registration Fees (MGMS Member | Non-MGMS Member)
- Student: £100 | £125
- Academic non-student: £150 | £175
- Industry: £200 | £225
The early bird deadline for registrations is 23:59 GMT on Friday 23rd February, after which prices will increase by £40.
The 3rd ADC Analytical Development Summit is your only industry-dedicated meeting providing you with the key insights to ensure you are developing a high-quality ADC product within regulatory boundaries.
Next year’s program promises to give you even more focused content to better quantify DAR and drug distribution, overcome species separation challenges, and better utilize impurity assays to measure free-linker drug and process-related impurities.
Get an exclusive sneak peek of the agenda here.
Not only is this meeting packed with technical content that will allow you to influence, gain a deeper understanding, and improve product quality, but it will also give you the opportunity to interact with industry experts including:
- Nailing Zhang, Lead Biologist, FDA
- Linda Nelson, Executive Director, RA-CMC, Daiichi Sankyo
- David Lee, Executive Director, Analytical Chemistry, Mersana Therapeutics
- Chris Woods, Scientist, Analytical Development, Seagen
- Madhumati Mukherjee, Senior Scientist, AstraZeneca
- Dengyun (Daisy) Sun, Principal Scientist, Cell Based Sciences, Merck & Co.
- Yan-Hui Liu, Director, Analytical Development, GSK
We hope you can join us to network with like-minded colleagues and scientists and have the in-depth technical conversations needed to address the common analytical bottlenecks in ADC development.
Antibody Society members save 10% off the conference registration– contact membership@antibodysociety.org or visit the Members Only section of the website to find the discount code.
Now into our 8th year, CHI’s Immuno-Oncology Summit Europe is the premier event for immuno-oncology professionals who want to learn about the latest advancements and innovations in the field. The Summit will take place on 23-25 April 2024 in London, one of the world’s leading hubs for biomedical research and clinical development.
With a comprehensive agenda encompassing four distinct yet related programs – Modulating the Tumour Microenvironment, Next Generation Cell-Based Immunotherapies, Bispecific and Multi-specific Antibody Therapeutics, and Therapeutic Cancer Vaccines, the Summit promises to be a forum for the exchange of cutting-edge research, and a platform for collaboration among the global immuno-oncology community.
Learn more and register today at Immuno-OncologyEurope.com
Antibody Society members save 20% off the conference registration– contact membership@antibodysociety.org or visit the Members Only section of the website to find the discount code.
May 2024
Celebrating 20 years!
The PEGS Boston Summit brings together leading experts at the forefront of biologics innovation, providing insights into the latest technologies, research, and advancements in drug development, protein and antibody engineering, immunotherapy, immunogenicity, expression platforms, multispecific antibodies, machine learning and AI in biologics, and more.
PEGS Boston features main conference sessions as well as deep dive training seminars and topic-focused short courses. The PEGS Boston Summit is your number one resource for protein engineering updates and is the conference to attend in 2024 to network, collaborate, and learn from the industry’s best.
Registration is open!
Antibody Society members save 20% off the conference registration– contact membership@antibodysociety.org or visit the Members Only section of the website to find the discount code.
June 2024
15 years after the first AIRR-seq sequencing, what have we learned in the basic and biomedical research fields? What is next?
AIRR Community Meeting VII: Learnings and Perspectives that will be held at the University of Porto in Porto, Portugal from June 3-6, 2024. Registration will open at the end of January. Learn more here.
Antibody Engineering & Therapeutics Europe 2024
Hybrid 4 – 6 June 2024 | London ExCel Platinum Suite
Are you seeking the latest antibody and protein research updates? Do you want to hear from pioneers who are shaping the field?
Be part of the #1 European antibody engineering conference from 4 – 6 June 2024. Created in conjunction with The Antibody Society, this year’s conference is coming to London – a true hub of the antibody community. Boasting 9 topic streams covering the need to know updates in industry, you will dive into:
- Fc Engineering
- Novel Approaches to Antibody Discovery
- Challenges in Discovery & Optimization of Multispecific Antibodies
- Agonist Antibodies
- Conditionally Active Biotherapeutics
- Emerging Modalities: ADCs, Degraders and Beyond
- Computational Approaches to Antibody Discovery and Optimization
- Co-Stimulatory Antibodies and Combination Approaches in Oncology
- Antibody Theranostics
Download the agenda here
There’s no better place to get the most critical updates that will help you to accelerate your path to market. Don’t miss your opportunity to be part of the discussions shaping the industry.
Antibody Society members save 15% off the conference registration– contact membership@antibodysociety.org or visit the Members Only section of the website to find the discount code.
With a storm of collaborations and novel innovations happening, all eyes are turning towards the APAC region for the next best thing when it comes to antibody-drug conjugate development. The 3rd World ADC Asia (June 25-27, 2024 | Incheon, South Korea) is back to unite the growing community of Asian-based drug developers.
The 3-day agenda has been designed to allow insightful discussions into your most pressing challenges, novel payloads, identifying unique targets, stable linker chemistries, working through manufacturing and regulatory hurdles, and more to boost ADC development and innovation.
Take a look at the full agenda here.
With a stellar lineup of 25+ industry-leading speakers from within Asia, here is a snapshot of who you could meet this June:
- Jinwon Jung, Senior Director, ABL Bio
- Dohyun Nam, Chairman, Aimed Bio
- Ziping Wei, Chief Executive Officer, Bliss Biopharma
- Yasuyuki Kaneta, Senior Director, Daiichi Sankyo
- Masayuki Miyano, Principal Scientist, Eisai
- Jun Ge, Executive Director, Head of China Clinical Development, Gilead
- Tse Wen Chang, Founder & Chairman, Immunwork
- Sun-Hwa Lee, Chief Scientific Officer, Novelty Nobility
- Heidi Wang, Chief Executive Officer, OBI Pharma
- Hyun Yong Cho, Chief Scientific Officer, PinotBio
See the full speaker faculty and session details here.
We hope you can join us at this must-attend event for the ADC Community based in the APAC region where the East will meet the West to propel your ADC development further than ever before.
Antibody Society members save 10% off the conference registration– contact membership@antibodysociety.org or visit the Members Only section of the website to find the discount code.
